Presentation is loading. Please wait.

Presentation is loading. Please wait.

Disclosures Dr Scirica has received Dr Scirica has received honoraria for educational presentations (modest) from CV Therapeutics The study was supported.

Similar presentations


Presentation on theme: "Disclosures Dr Scirica has received Dr Scirica has received honoraria for educational presentations (modest) from CV Therapeutics The study was supported."— Presentation transcript:

1 Disclosures Dr Scirica has received Dr Scirica has received honoraria for educational presentations (modest) from CV Therapeutics The study was supported through a research grant (major) from CV Therapeutics.

2 September 5 th, 2007 Vienna The Effect of Ranolazine on the Incidence of Arrhythmias in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome: Results from the MERLIN-TIMI 36 Trial

3 Ranolazine in Ischemic Heart Disease Background New antianginal agent –Anti-ischemic action without clinically significant effect on HR or BP Novel mechanism of action –Inhibition of late I Na (Late phase of sodium current) Approved for treatment of chronic angina –  exercise time,  angina in selected pts Persistent concern b/c prolongation of QT –2-6 msec with approved doses –Theoretical risk of ventricular tachycardia

4 Relation Between Peak and Late I Na and Ventricular Action Potential Sodium Current (I Na ) nA Action Potential mV Background Late Peak 0 Twitch Normal Late I Na Augmented Late I Na (delayed or incomplete inactivation) Late Peak 0 Twitch Early after- depolarization

5 Consequences of Increased Consequences of Increased Late I Na Na + Overload Ischemia Heart Failure Genetic defects Drugs Na +- Ca 2+ Exchanger Ca 2+ Overload  Late I Na Electrical Dysfunction Afterpotentials (e.g., EAD and DAD) Transmural Dispersion of Repolarization (TDR) Prolonged Action Potential Ranolazine Arrhythmias

6 Background Sotalol, 100 µM Ranolazine Antzelevitch C., et al. Circ 2004; 110:904-910 No ↑ in Transmural Dispersion of Repolarization (TDR) Effects of Ranolazine in Experimental Models on Pro-Arrhythmic Substrate and Triggers However, the potential anti-arrhythmic actions of ranolazine have yet to be evaluated in humans TDR (msec) Concentration (µM) ↓ Early Afterdepolarization (EAD) Control Action Potential EAD Sotalol + Ranolazine 10 µM 0 20 40 60 80 100 01510100

7 UA/NSTEMI (Moderate-High Risk) Ranolazine IV to PO Placebo Matched IV/PO RANDOMIZE (1:1) Double-blind HolterContinuous 7-day recording Long-term Follow-up (Median 348 Days) Standard Therapy N = 6560

8 Primary Endpoint Results CV Death or MI (%)Recurrent Ischemia (%) Days from Randomization Ranolazine 13.9%* (N=3,279) Placebo 16.1%* (N=3,281) 0180360540 HR 0.87 (95% CI 0.76 to 0.99) P =0.030 0 5 10 15 20 0 5 10 15 0180360540 Ranolazine 10.4%* Placebo 10.5%* HR 0.99 (95% CI 0.85 to 1.15) P =0.87 20 Days from Randomization *KM Cumulative Incidence (%) at 12 months Primary Endpoint - CV Death, MI, or Recurrent Ischemia 21.8% for Ranolazine vs. 23.5% for Placebo HR 0.92 (95% CI 0.83 to 1.02), P = 0.11 Morrow DA et al, JAMA 2007;297(16):1775-83

9 7-day Continuous ECG (Holter) monitoring7-day Continuous ECG (Holter) monitoring –Started at randomization (mean duration 6.3 d) –Customized monitors and analysis software (DelMar Reynolds / Spacelabs) –Evaluated in TIMI Core Laboratory blinded to treatment and clinical outcome Sudden Cardiac Death through entire clinical follow-up (mean 12 months)Sudden Cardiac Death through entire clinical follow-up (mean 12 months) –Adjudicated by blinded Clinical Events Committee Methods Study Design

10 Clinically Significant ArrhythmiaClinically Significant Arrhythmia –VT >3 beats –SVT >120 bpm lasting >4 beats –New onset a-fib –Bradycardia 2.5 s Further ClassificationFurther Classification –Ventricular Tachycardia Non-sustained VT >8 beatsNon-sustained VT >8 beats Sustained VT (lasting >30 seconds)Sustained VT (lasting >30 seconds) Mono or Poly-morphicMono or Poly-morphic –Ventricular Pauses >3 s Arrhythmia Endpoints Analysis Study Design

11 Baseline Characteristics RANOLAZINE (n=3,162) PLACEBO (n=3,189) Age (yrs, median) Female (%) Prior MI (%) Prior heart failure (%) Prior vent arrhythmia (%) EF <40% (%) NSTEMI on admission (%) Beta-blocker (%) 64 36 34 17 3.9 13 51 90 64 34 17 3.8 14 51 89 Holter Cohort 6,351 pts (97% of entire trial) Results

12 Primary Arrhythmia Endpoints Results RANOLAZINE (%) PLACEBO (%) P value Ventricular Events VT > 3 beats52.060.6<0.001 Supraventricular Events SVT >4 beats44.755.0<0.001 New-onset atrial fib1.72.40.08 Bradycardic Events Brady 2.5s 39.846.6<0.001 Pause > 3 sec3.14.30.01

13 First Occurrence of Ventricular Tachycardia Lasting > 8 Beats Results 0 2 4 6 8 10 024487296120144168 Hours from randomization Incidence of VT > 8 beats (%) RANOLAZINE PLACEBO RR 0.63 95%CI 0.52, 0.76 p<0.001 RR 0.67 p=0.008 RR 0.65 p<0.001 8.3% 5.3%

14 Incidence of VT >8 Beats in Subgroups Results RR 0.72 p<0.001 RR 0.53 p=0.001 RR 0.53 p=0.013 RR 0.66 p<0.001 Ejection Fraction >40%<40% Baseline QT c (msec) <450>450 Ranolazine Placebo

15 No Ischemia on cECG Ischemia on cECG RANOLAZINE (%) PLACEBO (%) p value 5.0 6.3 8.3 <0.001 0.112 Relative Risk (95% CI) Incidence of VT >8 Beats in High-risk Subgroups Results TRS 0-4 TRS 5-7 No Prior HF Prior HF 5.5 4.4 5.2 5.4 8.2 8.9 8.1 9.3 <0.001 0.001 <0.001 0.013 0.1 110 EF > 40% EF < 40% QTc <450 msec QTc > 450 msec 5.3 8.8 5.2 5.6 7.3 16.6 7.8 10.5 0.011 0.005 <0.001 0.002 P values for interaction >0.05

16 Ventricular Tachycardia Events Results RANOLAZINE (%) PLACEBO (%) P value Polymorphic VT > 8 beats 1.21.40.40 Sustained VT (> 30s)0.44 0.98 Monomorphic VT0.130.220.37 Polymorphic VT0.320.220.46

17 Sudden Cardiac Death Through Follow-up (mean 12 months) Results RANOLAZINE (%) PLACEBO (%) P value Overall 1.71.90.36 EF >40%1.5 0.48 EF <40%2.74.90.07 QTc <450 msec1.41.60.86 QTc >450 msec3.0 0.27 TRS 0-41.21.30.47 TRS 5-73.53.90.73 No Prior HF1.21.30.63 Prior HF4.14.30.58 P values for interaction >0.05

18 Among patients with ACS, ranolazine, an inhibitor of late I Na, has anti-arrhythmic effects as assessed by Holter monitoringAmong patients with ACS, ranolazine, an inhibitor of late I Na, has anti-arrhythmic effects as assessed by Holter monitoring In particular, patients treated with ranolazine had fewer episodes of VT > 8 beats, SVT, and ventricular pauses > 3 secondsIn particular, patients treated with ranolazine had fewer episodes of VT > 8 beats, SVT, and ventricular pauses > 3 seconds Consistent effect in several high-risk sub- groupsConsistent effect in several high-risk sub- groups Conclusions Conclusions

19 This is the 1 st clinical report of potential anti- arrhythmic actions of ranolazine and supports anti-arrhythmic findings in experimental modelsThis is the 1 st clinical report of potential anti- arrhythmic actions of ranolazine and supports anti-arrhythmic findings in experimental models There was no evidence for a significant excess risk of polymorphic ventricular tachycardia or sudden cardiac deathThere was no evidence for a significant excess risk of polymorphic ventricular tachycardia or sudden cardiac death Studies specifically designed to evaluate the potential role of ranolazine as an anti- arrhythmic agent are warrantedStudies specifically designed to evaluate the potential role of ranolazine as an anti- arrhythmic agent are warranted Conclusions (cont.) Conclusions


Download ppt "Disclosures Dr Scirica has received Dr Scirica has received honoraria for educational presentations (modest) from CV Therapeutics The study was supported."

Similar presentations


Ads by Google